PARP Inhibitor Biomarkers Market Analysis Report 2025: Market to Grow by a CAGR of 8.3 to 2033, Driven by Government Incentives, Popularity of Virtual Assistants, and Strategic Partnerships

Key Insights

The size of the PARP Inhibitor Biomarkers market was valued at USD XXX Million in 2023 and is projected to reach USD XXX Million by 2032, with an expected CAGR of 8.3% during the forecast period.Molecular markers can be used to identify the most probable responders to the treatment with PARP inhibitors. They are called PARP inhibitor biomarkers.The drugs in the PARP inhibitor class target the poly (ADP-ribose) polymerase enzyme involved in DNA repair.   Such cancer types include ovarian, breast, and prostate cancers, all with defects in the DNA repair pathways, thus rendering them susceptible to PARP inhibitors. With identification of patients by these biomarkers, treatment choices can be made more appropriately by healthcare providers for better patient outcomes.

Market Concentration & Characteristics

The PARP inhibitor biomarkers market is moderately concentrated, with a few major players holding a significant share of the market. These players include Agilent Technologies, Inc., Ambry Genetics, Amoy Diagnostics Co., Ltd., Centogene N.V, Illumina, Inc., Invitae Corporation, Myriad Genetics, Inc., Neogenomics, Inc., QIAGEN N.V., and Thermo Fisher Scientific Inc.

The market is characterized by innovation, as companies are continuously developing new and more sensitive biomarker tests. The market is also impacted by regulations, as biomarker tests must be approved by regulatory authorities before they can be used in clinical practice.

Key Region or Country & Segment to Dominate the Market

North America is the largest market for PARP inhibitor biomarkers, followed by Europe and Asia Pacific. This is due to the high prevalence of cancer in these regions and the early adoption of PARP inhibitors as a treatment for cancer.

The "Kits" segment is expected to dominate the market throughout the forecast period. This is due to the increased demand for biomarker testing kits for the identification of patients who are more likely to benefit from PARP inhibitor therapy.

Driving Forces

The increasing prevalence of cancer is a major driver of the PARP inhibitor biomarkers market. According to the World Health Organization (WHO), cancer is a leading cause of death worldwide, with approximately 10 million deaths in 2020. The growing adoption of PARP inhibitors as a treatment for cancer is also driving the market growth. PARP inhibitors have been shown to be effective in treating various types of cancer, and they are becoming the standard of care for certain types of cancer.

Challenges and Restraints

The high cost of biomarker testing is a major challenge for the PARP inhibitor biomarkers market. Biomarker testing can be expensive, which can limit access to testing for patients. The lack of awareness about biomarker testing is also a challenge for the market. Many patients and physicians are not aware of the benefits of biomarker testing, which can lead to underutilization of testing.

Emerging Trends

The development of new and more sensitive biomarker tests is a major trend in the PARP inhibitor biomarkers market. Companies are continuously investing in research and development to develop new tests that can identify patients who are more likely to benefit from PARP inhibitor therapy. The use of artificial intelligence (AI) in biomarker testing is also a growing trend. AI can be used to analyze large datasets of patient data to identify new biomarkers and develop more accurate tests.

PARP Inhibitor Biomarkers Industry News

• In January 2024, Myriad Genetics, Inc., a prominent figure in genetic testing and precision medicine, finalized an agreement to acquire specific assets from Intermountain Precision Genomics’ (IPG) laboratory division. These assets included the Precise Tumor Test, the Precise Liquid Test, and IPG’s CLIA-certified laboratory located in St. George, Utah. This strategic acquisition is expected to bolster Myriad Genetics' market presence in genetic testing and precision medicine, positioning the company competitively within the industry.

Leading Players in the PARP Inhibitor Biomarkers Market

• Agilent Technologies, Inc.
• Ambry Genetics
• Amoy Diagnostics Co., Ltd.
• Centogene N.V
• Illumina, Inc.
• Invitae Corporation
• Myriad Genetics, Inc.
• Neogenomics, Inc.
• QIAGEN N.V.
• Thermo Fisher Scientific Inc.

PARP Inhibitor Biomarkers Market Segmentation

1. Product

• 1.1. Kits
• 1.2. Assays

2. Service

• 2.1. BRCA (Breast cancer gene) 1 & 2 testing
• 2.2. HRD (Homologous recombination deficiency) testing
• 2.3. HRR (Homologous recombination repair) testing
• 2.4. Other services

3. Application

• 3.1. Breast cancer
• 3.2. Ovarian cancer
• 3.3. Other applications

4. End-use

• 4.1. Hospitals and clinics
• 4.2. Diagnostic laboratories
• 4.3. Academic and research institutes
• 4.4. Other end-users

PARP Inhibitor Biomarkers Market Segmentation By Geography

1. North America

• 1.1. U.S.
• 1.2. Canada

2. Europe

• 2.1. Germany
• 2.2. UK
• 2.3. France
• 2.4. Spain
• 2.5. Italy
• 2.6. Netherlands
• 2.7. Rest of Europe

3. Asia Pacific

• 3.1. Japan
• 3.2. China
• 3.3. India
• 3.4. Australia
• 3.5. South Korea
• 3.6. Rest of Asia Pacific

4. Latin America

• 4.1. Brazil
• 4.2. Mexico
• 4.3. Argentina
• 4.4. Rest of Latin America

5. Middle East and Africa

• 5.1. Saudi Arabia
• 5.2. South Africa
• 5.3. UAE
• 5.4. Rest of Middle East and Africa